Meyka Pro banner
Sight Sciences, Inc.

Sight Sciences, Inc. Fundamental Analysis (NASDAQ: SGHT)

SGHT●NASDAQ
HealthcareMedical - Devices
$11.01
$0.93(9.23%)
U.S. Market opens in 15h 50m

Sight Sciences, Inc. Fundamental Analysis (NASDAQ: SGHT)

Sight Sciences, Inc. (NASDAQ: SGHT) shows weak financial fundamentals with a PE ratio of -19.16, profit margin of -32.13%, and ROE of -51.66%. The company generates $0.1B in annual revenue with weak year-over-year growth of -3.13%.

Key Strengths

Cash Position12.76%
PEG Ratio-0.32
Current Ratio5.04

Areas of Concern

ROE-51.66%
Operating Margin-29.52%
We analyze SGHT's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -57.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-57.9/100

We analyze SGHT's fundamental strength across five key dimensions:

Efficiency Score

Weak

SGHT struggles to generate sufficient returns from assets.

ROA > 10%
-27.06%

Valuation Score

Excellent

SGHT trades at attractive valuation levels.

PE < 25
-19.16
PEG Ratio < 2
-0.32

Growth Score

Moderate

SGHT shows steady but slowing expansion.

Revenue Growth > 5%
-3.13%
EPS Growth > 10%
28.16%

Financial Health Score

Excellent

SGHT maintains a strong and stable balance sheet.

Debt/Equity < 1
0.86
Current Ratio > 1
5.04

Profitability Score

Weak

SGHT struggles to sustain strong margins.

ROE > 15%
-5166.18%
Net Margin ≥ 15%
-32.13%
Positive Free Cash Flow
No

Key Financial Metrics

Is SGHT Expensive or Cheap?

P/E Ratio

SGHT trades at -19.16 times earnings. This suggests potential undervaluation.

-19.16

PEG Ratio

When adjusting for growth, SGHT's PEG of -0.32 indicates potential undervaluation.

-0.32

Price to Book

The market values Sight Sciences, Inc. at 11.15 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

11.15

EV/EBITDA

Enterprise value stands at -23.88 times EBITDA. This is generally considered low.

-23.88

How Well Does SGHT Make Money?

Net Profit Margin

For every $100 in sales, Sight Sciences, Inc. keeps $-32.13 as profit after all expenses.

-32.13%

Operating Margin

Core operations generate -29.52 in profit for every $100 in revenue, before interest and taxes.

-29.52%

ROE

Management delivers $-51.66 in profit for every $100 of shareholder equity.

-51.66%

ROA

Sight Sciences, Inc. generates $-27.06 in profit for every $100 in assets, demonstrating efficient asset deployment.

-27.06%

Following the Money - Real Cash Generation

Operating Cash Flow

Sight Sciences, Inc. generates limited operating cash flow of $-16.91M, signaling weaker underlying cash strength.

$-16.91M

Free Cash Flow

Sight Sciences, Inc. generates weak or negative free cash flow of $-16.90M, restricting financial flexibility.

$-16.90M

FCF Per Share

Each share generates $-0.31 in free cash annually.

$-0.31

FCF Yield

SGHT converts -3.03% of its market value into free cash.

-3.03%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-19.16

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.32

vs 25 benchmark

P/B Ratio

Price to book value ratio

11.15

vs 25 benchmark

P/S Ratio

Price to sales ratio

6.19

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.86

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.04

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.52

vs 25 benchmark

ROA

Return on assets percentage

-0.27

vs 25 benchmark

ROCE

Return on capital employed

-0.31

vs 25 benchmark

How SGHT Stacks Against Its Sector Peers

MetricSGHT ValueSector AveragePerformance
P/E Ratio-19.1630.84 Better (Cheaper)
ROE-51.66%573.00% Weak
Net Margin-32.13%5349.00% Weak
Debt/Equity0.86-0.03 (disorted) Distorted
Current Ratio5.045.76 Strong Liquidity
ROA-27.06%-254.00% (disorted) Weak

SGHT outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Sight Sciences, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

151.01%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

0.67%

Industry Style: Defensive, Growth, Innovation

Growing

FCF CAGR

17.23%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ